Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

VOQUEZNA shows strong modeled cost-effectiveness but lacks realised financial impact data.

What the company is saying

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is highlighting new cost-effectiveness data for VOQUEZNA (vonoprazan), presented at the American College of Gastroenterology’s 2026 Annual Scientific Meeting. The company emphasizes that predictive modeling projects VOQUEZNA to be cost-effective versus proton pump inhibitors (PPIs) for Erosive GERD, with incremental cost-effectiveness ratios (ICERs) per QALY of $28,402 for the overall population and $18,878 for severe cases, both well below the $100,000 threshold. Steve Basta, President and CEO, frames these results as evidence of potential healthcare savings and reduced downstream complications over a patient’s lifetime. The announcement also spotlights additional analyses, including a post-hoc study showing VOQUEZNA’s efficacy across BMI subgroups and a retrospective real-world cohort study showing that patients prescribed VOQUEZNA had more severe baseline GERD than those on PPIs. The company draws attention to the breadth of independent research—38 abstracts—presented at the conference, covering safety, efficacy, and use in diverse populations. The tone is confident and positions VOQUEZNA as a clinically differentiated and economically attractive option, but the emphasis remains on modeled projections and scientific interest rather than realised financial results.

What the data suggests

The disclosed ICERs per QALY for VOQUEZNA versus PPIs are $28,402 for the overall Erosive GERD population and $18,878 for severe cases, both substantially below the $100,000 cost-effectiveness benchmark. These figures are based on a Markov model projecting outcomes for commercially insured U.S. adults with a mean age of 51.3 years over a lifetime horizon. Real-world data show that 1,304 patients initiated VOQUEZNA compared to 1,304,683 for PPIs, with VOQUEZNA patients having higher rates of Erosive GERD (64.6% vs. 32.3%), hiatal hernia (32.4% vs. 10.7%), and prior PPI use (62.1% vs. 38.2%). A post-hoc analysis found VOQUEZNA improved heartburn-free days across all BMI subgroups, with no significant treatment-by-BMI interaction. The announcement does not provide realised cost savings, revenue, or profit data—only modeled projections and clinical endpoints. The breadth of independent research, including 38 abstracts, signals strong scientific interest but does not substitute for financial performance metrics. Overall, the data supports VOQUEZNA’s clinical differentiation and modeled economic value, but does not demonstrate actual financial impact for Phathom.

Analysis

The announcement is upbeat, emphasizing VOQUEZNA's projected cost-effectiveness and potential healthcare savings over a lifetime horizon. However, the majority of the key claims regarding economic value, cost savings, and reduced complications are based on predictive modeling (Markov model) and are inherently forward-looking, with benefits expected to accrue over patients' lifetimes—well beyond the near term. While the ICER per QALY figures are numerically specific, they are model outputs, not realised financial or clinical outcomes. The release does provide some realised data (post-hoc analysis, real-world cohort study, and regulatory approval status), but these are largely descriptive and do not quantify actual cost savings or profitability. There is no disclosure of company-level financials (revenue, profit, cash flow), so the true_signal cannot exceed weak_positive. The tone is moderately hyped by repeatedly highlighting 'potential' and 'projected' benefits without corresponding realised impact.

Risk flags

• ●The primary risk is that all economic value claims are based on predictive modeling rather than realised outcomes, so actual cost savings and adoption rates may differ from projections. If payers or providers do not accept the modeled assumptions, commercial uptake could lag expectations.
• ●No realised financial data—such as revenue, profit, or actual healthcare cost savings—are disclosed, making it impossible to assess the current business impact or trajectory. This limits investor visibility into the product’s true market performance.
• ●The real-world cohort study shows that VOQUEZNA is prescribed to a more severe GERD population, which may complicate direct comparisons with PPIs and could affect generalizability of modeled cost-effectiveness.
• ●The announcement relies heavily on scientific interest and independent research, but many of these studies cover investigational uses not approved by the FDA, introducing regulatory and clinical adoption risk.
• ●Long-term projections are inherently uncertain, especially in the U.S. pharmaceutical market where reimbursement, competition, and clinical guidelines can shift over time, potentially undermining modeled economic value.

Bottom line

Phathom’s announcement provides detailed modeled evidence that VOQUEZNA is cost-effective for Erosive GERD, with ICERs per QALY of $28,402 and $18,878 for overall and severe populations, respectively—well below the $100,000 threshold. While the clinical and economic modeling is robust and supported by real-world and post-hoc analyses, there is no disclosure of realised financial outcomes, sales, or profit attributable to VOQUEZNA. The product is being prescribed to more severe GERD patients, which may affect the generalizability of the findings. The breadth of independent research underscores scientific interest, but many studies are investigational and not FDA-approved, adding regulatory risk. All projected benefits are long-term and depend on payer acceptance and real-world adoption. For investors, the key takeaway is that VOQUEZNA’s modeled cost-effectiveness is promising, but tangible financial impact remains unproven and distant. Future updates should focus on realised sales, adoption rates, and payer coverage to substantiate the economic value claims.

Announcement summary

(NASDAQ:PHAT) Phathom Pharmaceuticals, Inc. announced new cost-effectiveness data for VOQUEZNA (vonoprazan) at the American College of Gastroenterology’s (ACG) 2026 Annual Scientific Meeting. A predictive cost-effectiveness analysis projected VOQUEZNA to be cost-effective compared with proton pump inhibitors (PPIs) for healing and maintenance of Erosive Esophagitis or Erosive GERD over patients’ lifetimes, with potential cost savings at net price based on clinical healing and maintenance data and fewer anticipated downstream complications. The Markov model used in the analysis projected lifetime clinical and economic outcomes for commercially insured U.S. adults with Erosive GERD, beginning at a mean age of 51.3 years. VOQUEZNA was projected to result in fewer downstream complications, such as esophageal adenocarcinoma and related deaths, compared with PPIs in both overall and severe (Los Angeles Grades C and D) Erosive GERD populations. At WAC price, VOQUEZNA was projected to be cost-effective versus PPIs with incremental cost-effectiveness ratios (ICERs) per quality-adjusted life year (QALY) of $28,402 for the overall population and $18,878 for the severe population. The standard minimum threshold of cost-effectiveness is an ICER per QALY of less than $100,000. Additional analyses included a post-hoc analysis of VOQUEZNA treatment effects across BMI subgroups in Non-Erosive GERD, which found improvements in 24-hour heartburn-free days and both daytime and nighttime heartburn control with VOQUEZNA versus placebo across BMI subgroups (<30, ≥30, and ≥35 kg/m²), with no significant treatment-by-BMI interaction. Baseline heartburn and regurgitation symptom scores were similar across BMI subgroups, with greater improvement following vonoprazan versus placebo in each group. A retrospective cohort study using linked EHR and claims data found that patients initiating VOQUEZNA (n=1,304) had a more severe baseline GERD profile than those initiating a prescription PPI (n=1,304,683), including higher rates of Erosive GERD (64.6% vs. 32.3%), hiatal hernia (32.4% vs. 10.7%), and use of two or more prior prescription PPI lines of therapy (62.1% vs. 38.2%). Vonoprazan was the subject of 38 independent, investigator-initiated abstracts presented at ACG 2026, covering topics such as GI and renal safety outcomes, H. pylori eradication, GI bleeding, peptic ulcers, and use in special populations including patients from China, India, and Japan. The independent research included real-world data from China evaluating vonoprazan in patients with reflux esophagitis, including elderly patients and those with comorbid anxiety or depression, and multicenter data from India on gut resistome remodeling and refractory GERD outcomes. VOQUEZNA is approved in the U.S. for the treatment of adults with Erosive Esophagitis (Erosive GERD), relief of heartburn associated with Erosive and Non-Erosive GERD, and for the treatment of H. pylori infection in combination with amoxicillin or amoxicillin and clarithromycin. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and other countries in Asia and Latin America. Steve Basta, President and Chief Executive Officer of Phathom, stated that the new findings highlight the potential cost-effectiveness of VOQUEZNA for patients with Erosive GERD and provide insights into how clinical outcomes may translate into healthcare savings over time.

Disagree with this article?